Literature DB >> 24118394

Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism.

X Hu1, Y Bonde, G Eggertsen, M Rudling.   

Abstract

OBJECTIVE: Bile acid (BA) synthesis is regulated by negative feedback end-product inhibition, initiated by farnesoid X receptors (FXRs) in liver and gut. Studies on cholic acid (CA)-free Cyp8b1(-/-) mice have concluded that CA is a potent suppressor of BA synthesis. Cyp8b1(-/-) mice have increased BA synthesis and an enlarged BA pool, a phenotype shared with bile-duct-ligated, antibiotics-administered and with germ-free mice. Studies on such mice have concluded BA synthesis is induced due to reduced hormonal signalling by fibroblast growth factor (FGF)15 from intestine to liver. A mutual finding in these models is that potent FXR-agonistic BAs are reduced. We hypothesized that the absence of the potent FXR agonist deoxycholic acid (DCA) may be important for the induction of BA synthesis in these situations.
DESIGN: Two of these models were investigated, antibiotic treatment and Cyp8b1(-/-) mice and their combination. Secondary BA formation was inhibited by ampicillin (AMP) given to wild-type and Cyp8b1(-/-) mice. We then administered CA, chenodeoxycholic acid (CDCA) or DCA to AMP-treated Cyp8b1(-/-) mice.
RESULTS: Our data show that the phenotype of AMP-treated wild-type mice resembles that of Cyp8b1(-/-) mice with fourfold induced Cyp7a1 expression, increased intestinal apical sodium-dependent BA transporter expression and increased hepatic BA levels. We also show that reductions in the FXR-agonistic BAs CDCA, CA, DCA or lithocholic acid cannot explain this phenotype; instead, it is likely due to increases in levels of α- and β-muricholic BAs and ursodeoxycholic acid, three FXR-antagonistic BAs.
CONCLUSIONS: Our findings reveal a potent positive feedback mechanism for regulation of BA synthesis in mice that appears to be sufficient without endocrine effects of FGF15 on Cyp7a1. This mechanism will be fundamental in understanding BA metabolism in both mice and humans.
© 2013 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  antagonist; apical sodium-dependent bile acid transporter; fibroblast growth factor 15; muricholic acid; steroid 12-alpha hydroxylase

Mesh:

Substances:

Year:  2013        PMID: 24118394     DOI: 10.1111/joim.12140

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  41 in total

1.  Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.

Authors:  Kyosuke Fujita; Yusuke Iguchi; Mizuho Une; Shiro Watanabe
Journal:  Lipids       Date:  2017-03-17       Impact factor: 1.880

Review 2.  Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?

Authors:  Lu Jiang; Bernd Schnabl
Journal:  Physiology (Bethesda)       Date:  2020-07-01

Review 3.  Intestinal Absorption of Bile Acids in Health and Disease.

Authors:  Alexander L Ticho; Pooja Malhotra; Pradeep K Dudeja; Ravinder K Gill; Waddah A Alrefai
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

Review 4.  Bile acids as metabolic regulators.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Curr Opin Gastroenterol       Date:  2015-03       Impact factor: 3.287

Review 5.  Interaction of gut microbiota with bile acid metabolism and its influence on disease states.

Authors:  Alexander Khoruts; Michael J Sadowsky; Christopher Staley; Alexa R Weingarden
Journal:  Appl Microbiol Biotechnol       Date:  2016-11-25       Impact factor: 4.813

6.  Dietary hyodeoxycholic acid exerts hypolipidemic effects by reducing farnesoid X receptor antagonist bile acids in mouse enterohepatic tissues.

Authors:  Shiro Watanabe; Kyosuke Fujita
Journal:  Lipids       Date:  2014-09-05       Impact factor: 1.880

Review 7.  Bile Acid Metabolism in Liver Pathobiology.

Authors:  John Y L Chiang; Jessica M Ferrell
Journal:  Gene Expr       Date:  2018-01-11

8.  Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice.

Authors:  Zidong Donna Fu; Julia Yue Cui; Curtis D Klaassen
Journal:  J Lipid Res       Date:  2014-10-02       Impact factor: 5.922

9.  Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice.

Authors:  Yunpeng Qi; Changtao Jiang; Jie Cheng; Kristopher W Krausz; Tiangang Li; Jessica M Ferrell; Frank J Gonzalez; John Y L Chiang
Journal:  Biochim Biophys Acta       Date:  2014-05-04

10.  PBDEs Altered Gut Microbiome and Bile Acid Homeostasis in Male C57BL/6 Mice.

Authors:  Cindy Yanfei Li; Joseph L Dempsey; Dongfang Wang; SooWan Lee; Kris M Weigel; Qiang Fei; Deepak Kumar Bhatt; Bhagwat Prasad; Daniel Raftery; Haiwei Gu; Julia Yue Cui
Journal:  Drug Metab Dispos       Date:  2018-05-16       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.